Monogenic obesity; using drugs to bypass the problem
MetadataShow full item record
Coll, a. (2018). Monogenic obesity; using drugs to bypass the problem. Cell Metabolism, 28 (1), 1-2. https://doi.org/10.1016/j.cmet.2018.06.015
Safe and effective pharmacological treatments for severe obesity remain scarce. In this issue, Iepsen et al. show that obese patients with pathogenic melanocortin 4 receptor mutations, the most common form of monogenic obesity, lose weight with glucagon-like peptide 1 (GLP-1) receptor agonist therapy.
A.P.C. is supported by the Medical Research Council (MRC Metabolic Diseases Unit [MRC_MC_UU_12012/1]).
Medical Research Council (MC_UU_12012/1)
Medical Research Council (MC_UU_12012/5)
External DOI: https://doi.org/10.1016/j.cmet.2018.06.015
This record's URL: https://www.repository.cam.ac.uk/handle/1810/283544
Attribution-NonCommercial-NoDerivatives 4.0 International